The initial success of Sildenafil undeniably reshaped the medication landscape, but placing funds in companies primarily reliant on generic versions presents a uncertain picture. While early profits were substantial, the expiration of patents and the appearance of less expensive alternatives have eroded the customer base. Thus, a thorough evaluatio